Scott L Friedman

Scott L Friedman, MD

  • Professor of Medicine, Liver Disease
    Professor, Pharmacology and Systems Therapeutics Chief, Division of Liver Diseases
    Director, Fibrosis Research Center
    Director, Mount Sinai Alcoholic Liver Disease Research Center
    Director, SinaInnovations

Research Topics:

Aerodigestive Tract, Apoptosis/Cell Death, Cancer Genetics, Cell Biology, Cell Transformation, Developmental Biology, Epithelial Cells, Extracellular Matrix, Fibrosis, Growth Factors and Receptors, Hepatitis C Virus, Integrins, Knockout Mice, Liver, Macrophage, Metastasis, Molecular Biology, Organogenesis, Oxidative Stress, Phosphorylation, Proteases, Receptors, Signal Transduction, Stem Cells, Transcription Factors, Transcriptional Activation and Repression, Transgenic Mice, Tumor Suppressor Genes, Tumorigenesis, Vascular Development, Wound Healing

Dr. Scott L. Friedman is the Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases, at the Icahn School of Medicine at Mount Sinai.  He has performed pioneering research into the underlying causes of scarring, or fibrosis associated with chronic liver disease, affecting millions worldwide. Dr. Friedman was the first to isolate and characterize the hepatic stellate cell, the key cell type responsible for scar production in liver. His work has spawned an entire field that is now realizing its translational and therapeutic potential, with new anti-fibrotic therapies for liver disease reaching clinical trials.  Dr. Friedman’s work has been continuously funded by the NIH since 1985; he was awarded his first faculty NIH grant (RO1) in 1986 at the age of 31.  

                        A 1979 graduate of the Icahn School of Medicine at Mount Sinai, he served as the President of Alpha Omega Alpha Honor Society and was an awardee of the Arthur Aufses, Sr. Prize in Surgery. After graduation Dr. Friedman was a Medical Resident at the Beth Israel Hospital, Harvard Medical School, Boston, then a Gastroenterology Fellow at UCSF before assuming a faculty position there which he held for ten years. During a 1995-96 sabbatical from UCSF he was a Senior Fulbright Scholar and Visiting Professor at the Weizmann Institute of Science in Israel, in the laboratory of Professor Moshe Oren. Dr. Friedman has given invited honorary lectures throughout the world and has been a named lecturer or Visiting Professor at over 30 institutions worldwide.  He is widely recognized as a dynamic, effective speaker, and is also a respected author, with over 300 peer-reviewed publications. Dr. Friedman was a recipient in 1993 of the Saul Horowitz, Jr. Outstanding Alumnus Award from Mount Sinai. In 2003, Dr. Friedman was honored with the International Hans Popper Award by the Falk Foundation in Freiburg, Germany, in recognition of his outstanding contributions to the understanding of liver disease and its treatment.  He has mentored over 75 postdoctoral fellows and students, most of who remain in academic training programs or faculty. In addition to his laboratory research, Dr. Friedman is a respected clinician and teacher, and is listed among the "America’s Top Doctors".  He was awarded the Department of Medicine’s Berson Housestaff Teaching Award in 2006, and in 2009 was recognized as a Master Educator by the Mount Sinai Institute of Medical Education.  In 2012 he was awarded the European Association for the Study of Liver Diseases International Recognition Award in Barcelona, Spain, and in 2013 he was awarded the Shanghai Magnolia Gold Award by the Mayor of Shanghai and the China Friendship Award from the Premier of China in 2014 in recognition of his efforts to improve the health of the residents of Shanghai and China through his research achievements.

                        As Chief of the Division of Liver Diseases at Mount Sinai since 2001, Dr. Friedman has expanded the faculty from 5 to 25 individuals, increased NIH grant funding more than 5-fold, clinical trials income more than 10-fold, and overseen the creationof the largest liver fellowship in the United States.  He is formerly an Associate Editor of Hepatology, and is currently Associate Editor for the Journal of Hepatology, and Series Editor for the Mount Sinai Handbooks of Disease (to be published in 2014), and has served on multiple Editorial Boards.  He is on the Scientific Advisory Board of the US-Israel Binational Science Foundation and previously served on the Senior Advisory Council for the National Institute of Alcohol Abuse and Alcoholism.  He has been a member of the American Society of Clinical Investigation since 1995, the Association of American Physicians since 2004, and was elected as a Fellow of the American Gastroenterological Association in 2008, the Am. College of Physicians in 2013, the American Association for the Study of Liver Diseases in 2014 and the American Association for the Advancement of Science in 2015.   

                        As President of the American Assn for the Study of Liver Diseases in 2009 (the sixth Mount Sinai faculty member to hold this position), Dr. Friedman oversaw several major new initiatives that accelerated its growth and brought the Association to unmatched levels of growth, income and international visibility.

                        Most recently, Dr. Friedman’s appointment in 2012 as Dean for Therapeutic Discovery at Mount Sinai recognizes his unique strengths in translating basic science into novel diagnostics and therapeutics.  He currently consults for over 40 pharmaceutical and biotech companies and is widely viewed as one of the leading experts in fibrosis in the world.  In his role as Dean for Therapeutic Discovery, Dr. Friedman seeks to integrate the rapidly growing innovation ecosystem at Mount Sinai which includes Mount Sinai Innovation Partners, the Center for Technology Innovation and Entrepreneurship, and Experimental Therapeutics core facilities in order to accelerate the discovery, commercialization and translation of novel advances into new treatments for human disease.

Multi-Disciplinary Training Areas

Biophysics and Systems Pharmacology [BSP], Cancer Biology [CAB], Genetics and Genomic Sciences [GGS]